AstraZeneca (LON:AZN) Receives Buy Rating from Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Shore Capital in a research note issued on Friday, Marketbeat reports.

AZN has been the subject of several other research reports. Jefferies Financial Group reiterated a “buy” rating and issued a £150 price objective on shares of AstraZeneca in a research note on Monday, November 10th. Berenberg Bank lifted their price objective on AstraZeneca from £142 to £145 and gave the company a “buy” rating in a report on Tuesday, October 21st. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of £138.

AstraZeneca Stock Performance

LON:AZN traded down GBX 44 during mid-day trading on Friday, hitting £139.82. 293,375,938 shares of the stock were exchanged, compared to its average volume of 54,961,426. The firm’s 50-day simple moving average is £137.20 and its 200 day simple moving average is £123.34. The stock has a market capitalization of £216.76 billion, a price-to-earnings ratio of 23.23, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. AstraZeneca has a fifty-two week low of GBX 9,573.51 and a fifty-two week high of £144.10. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

Insider Transactions at AstraZeneca

In other news, insider Nazneen Rahman sold 297 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of £134.96, for a total transaction of £40,083.12. 0.14% of the stock is currently owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.